Overview

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With P

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
A multi-center, open-label study that will evaluate the safety/tolerability and pharmacodynamics as well as the pharmacokinetic profile (sub-population analysis), in 50 evaluable adolescents 12 to < 17 years of age.
Phase:
Phase 2
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.